Prodromal Lewy body disorder features in REM sleep behavior disorder with biomarker-defined synucleinopathy

Read full text
Authors: Daniel A. Weintraub, Michele K. York, Roseanne D. Dobkin, Anuprita R Nair, Ryan Kurth, David-Erick Lafontant, Chelsea Caspell‐Garcia, Roy N. Alcalay, Ethan G. Brown, Lana M. Chahine, Christopher Coffey, Tatiana Foroud
+13 more Douglas Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Andrew Siderowf, Cristina Simonet, Tanya Simuni, Cary Tanner, Thomas Francis Tropea, Aleksandar Videnović, The Parkinson's Progression Markers Initiative
Cited by: 0
References: 56

Abstract

ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker-defined synucleinopathy. Methods Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal, multi-center observational study. Participants included polysomnogram (PSG)-confirmed iRBD individuals who were cerebrospinal fluid (CSF) α-synuclein seed amplification assay positive with no clinical diagnosis of Parkinson’s disease or dementia with Lewy bodies, along with robust healthy controls (HCs). Clinical and biological features of prodromal PD and DLB, including mild cognitive impairment (MCI), subthreshold parkinsonism, and a range of neuropsychiatric, autonomic and sensory symptoms, were assessed. Results Compared with HCs ( N =136), iRBD participants ( N =197) demonstrated worse cognitive performance, including a lower cognitive summary score ( p

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Restless Legs Syndrome Research Sleep and Wakefulness Research

Publication details

Journal / source
medRxiv
Publication date
1 January 2026
Document type
Preprint